ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

122
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
Refresh
bullishLupin Ltd
24 Apr 2024 18:55Broker

Lupin Ltd - New Drugs Approvals Will Boost Future Prospects

The combined sales from these three drugs could potentially generate incremental sales of ~$100 Mn per year in the US market.

Logo
209 Views
Share
bullishLupin Ltd
18 Apr 2024 06:36Broker

Lupin Ltd - GSpiriva on a Healthy Growth Track, Headwinds Receding

This to result in $200-220 million sales on a quarterly basis. USFDA recently completed cGMP inspection of Dabhasa plant and zconcluded with no...

Logo
Sharekhan
167 Views
Share
bullishLupin Ltd
09 Feb 2024 20:05Broker

LUPIN Ltd - Margins Guidance Increased

The company’s sales increased by 20.2% YoY to Rs 5,197 Cr, and the growth was majorly led by its US business of $212 (+0.5% Q0Q).

Logo
413 Views
Share
bullishLupin Ltd
07 Aug 2023 21:27Broker

LUPIN Ltd - Positive Outlook Backed by the Launch of Niche Products

The company’s sales were up 28.6% YoY at Rs 4,330 Cr, and the growth was majorily led by its India business (+9.8% YoY), EMEA (+19.6% YoY)

Logo
265 Views
Share
bullishLupin Ltd
11 Jul 2023 09:19Broker

Pick of the Week: Lupin Ltd - 10 JULY 2023

Lupin is an innovation-led transnational pharmaceutical company. It, develops and commercializes a wide range of branded and generic formulations,...

Logo
248 Views
Share
x